修订版昏迷恢复量表的行为评估在重症监护病房意识障碍患者中安全可行
该单中心回顾性队列研究纳入2018年4月1日至2021年12月31日马里兰大学医学中心神经重症监护病房连续收治的蛛网膜下腔出血或脑出血患者,分析ICU期间系列CRS-R评估(<8分为植物状态/无反应觉醒综合征,≥8分为最小意识状态)的安全性及其与出院去向、治疗性功能和活动能力的关联。76例患者(22例SAH、54例ICH,中位年龄59岁,50%女性)共完成276次CRS-R评估,无不良事件。最终CRS-R<8分者出院至急性康复机构的比例为4.4%,≥8分者为41.9%(OR 13.4;95%CI 2.7-66.1;p<0.001)。最终CRS-R为MCS者住院期间完成更多治疗次数,活动能力和功能表现更好;与其他治疗评估工具相比,CRS-R预测出院去向的表现最佳(AUC 0.83;95%CI 0.72-0.94;p<0.0001)。作者认为,CRS-R指导的早期神经康复在出血性卒中合并意识障碍的ICU患者中似乎可行且安全,可能增加获得住院康复的机会,并可能对恢复产生持久获益;需进一步研究评估普适性和对长期结局的影响。
要点
- 76例出血性卒中后意识障碍患者共完成276次CRS-R评估,无不良事件发生。
- 最终CRS-R≥8分者出院至急性康复机构的比例为41.9%,<8分者为4.4%(OR 13.4;95%CI 2.7-66.1;p<0.001)。
- 最终CRS-R为MCS者住院期间完成更多治疗次数,活动能力和功能表现更好。
- 与其他治疗评估工具相比,CRS-R预测出院去向的表现最佳(AUC 0.83;95%CI 0.72-0.94;p<0.0001)。
- 作者认为CRS-R指导的早期神经康复在ICU中似乎可行且安全,可能增加获得住院康复的机会。
适用人群与场景
- 2018年4月1日至2021年12月31日在马里兰大学医学中心神经重症监护病房连续收治的蛛网膜下腔出血或脑出血患者,ICU住院期间接受系列CRS-R评估。
- 单中心研究,共76例(22例SAH,54例ICH,中位年龄59岁,50%女性)。
诊断标准与关键阈值
- CRS-R<8分为植物状态/无反应觉醒综合征(VS/UWS)。
- CRS-R≥8分为最小意识状态(MCS)。
研究设计与关键结果
- 回顾性队列研究,单中心,76例出血性卒中后意识障碍患者(22例SAH,54例ICH,中位年龄59岁,50%女性),共完成276次CRS-R评估,无不良事件。
- 最终CRS-R<8分者出院至急性康复机构的比例为4.4%,最终CRS-R≥8分者为41.9%(OR 13.4;95%CI 2.7-66.1;p<0.001)。
- 最终CRS-R为MCS者住院期间完成更多治疗次数,活动能力和功能表现更好。
- 与其他治疗评估工具相比,CRS-R预测出院去向的表现最佳(AUC 0.83;95%CI 0.72-0.94;p<0.0001)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性;作者在结论中提出需进一步研究评估普适性和对长期结局的影响。
对床旁实践的改变
- 作者认为,CRS-R指导的早期神经康复在出血性卒中合并意识障碍的ICU患者中似乎可行且安全,可能增加获得住院康复的机会,并可能对恢复产生持久获益。
- 作者提出需进一步研究评估普适性和对长期结局的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurate classification of disorders of consciousness (DoC) is key in developing rehabilitation plans after brain injury. The Coma Recovery Scale-Revised (CRS-R) is a sensitive measure of consciousness validated in the rehabilitation phase of care. We tested the feasibility, safety, and impact of CRS-R-guided rehabilitation in the ICU for patients with DoC after acute hemorrhagic stroke.
DESIGN: Retrospective cohort study.
SETTING: This single-center study was conducted in the neurocritical care unit at the University of Maryland Medical Center.
PATIENTS: We analyzed records from consecutive patients with subarachnoid hemorrhage (SAH) or intracerebral hemorrhage (ICH), who underwent serial CRS-R assessments during ICU admission from April 1, 2018, to December 31, 2021, where CRS-R less than 8 is vegetative state/unresponsive wakefulness syndrome (VS/UWS); CRS-R greater than or equal to 8 is a minimally conscious state (MCS).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Outcomes included adverse events during CRS-R evaluations and associations between CRS-R and discharge disposition, therapy-based function, and mobility. We examined the utility of CRS-R compared with other therapist clinical assessment tools in predicting discharge disposition. Seventy-six patients (22 SAH, 54 ICH, median age = 59, 50% female) underwent 276 CRS-R sessions without adverse events. Discharge to acute rehabilitation occurred in 4.4% versus 41.9% of patients with a final CRS-R less than 8 and CRS-R greater than or equal to 8, respectively (odds ratio [OR] 13.4; 95% CI, 2.7-66.1; p < 0.001). Patients with MCS on final CRS-R completed more therapy sessions during hospitalization and had improved mobility and functional performance. Compared with other therapy assessment tools, the CRS-R had the best performance in predicting discharge disposition (area under the curve: 0.83; 95% CI, 0.72-0.94; p < 0.0001).
CONCLUSIONS: Early neurorehabilitation guided by CRS-R appears to be feasible and safe in the ICU following hemorrhagic stroke complicated by DoC and may enhance access to inpatient rehabilitation, with the potential for lasting benefit on recovery. Further research is needed to assess generalizability and understand the impact on long-term outcomes.
参考来源
- Woodward MR, Wells CL, Arnold S, et al. Behavioral Assessment With the Coma Recovery Scale-Revised Is Safe and Feasible in Critically Ill Patients With Disorders of Consciousness. Crit Care Explor. 2024. PMID: 38912722. doi:10.1097/CCE.0000000000001101
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。